May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Acute Severe Visual Acuity Decrease After Combination Therapy for Wet Macular Degeneration
Author Affiliations & Notes
  • J. B. Davies
    Barnes Retina Institute, St. Louis, Missouri
    Washington University School of Medicine, St. Louis, Missouri
  • G. Shah
    Barnes Retina Institute, St. Louis, Missouri
  • K. Blinder
    Barnes Retina Institute, St. Louis, Missouri
  • E. Ryan
    Retina Consultants of Minneapolis, Minneapolis, Minnesota
  • M. Hughes
    Ophthalmic Consultants of Boston, Boston, Massachusetts
  • D. Sang
    Ophthalmic Consultants of Boston, Boston, Massachusetts
  • D. Callanan
    Texas Retina Associates, Fort Worth, Texas
  • R. Mittra
    Retina Consultants of Minneapolis, Minneapolis, Minnesota
  • J. Pearlman
    Retinal Consultants Medical Group, Sacramento, California
  • A. Sheybani
    Washington University School of Medicine, St. Louis, Missouri
  • Footnotes
    Commercial Relationships  J.B. Davies, None; G. Shah, None; K. Blinder, None; E. Ryan, None; M. Hughes, None; D. Sang, None; D. Callanan, None; R. Mittra, None; J. Pearlman, None; A. Sheybani, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5569. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. B. Davies, G. Shah, K. Blinder, E. Ryan, M. Hughes, D. Sang, D. Callanan, R. Mittra, J. Pearlman, A. Sheybani; Acute Severe Visual Acuity Decrease After Combination Therapy for Wet Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5569.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Combination therapy for wet macular degeneration, consisting of photodynamic therapy (PDT) with verteporfin in conjunction with vascular endothelial growth factor (VEGF) antagonists, is being investigated as an alternative approach to treatment of this disease. One known adverse event occurring after photodynamic therapy is acute severe visual acuity decrease, defined as loss of twenty or more ETDRS letters within seven days of treatment. This complication occurred in 4.4% of verteporfin-treated patients in the Verteporfin in Photodynamic Therapy Study. The purpose of this report is to describe the cases of acute severe visual acuity decrease in patients treated with combination therapy for wet macular degeneration.

Methods: : Retrospective, observational, multi-center case series. Clinical features under review include lesion type and size by fluorescein angiography, timing of therapy, choice of anti-VEGF agent used, full vs. reduced fluence PDT, visual acuity, and ocular coherence tomography.

Results: : There were no cases of permanent severe vision loss out of 322 patients treated with combination therapy in our series, although twelve patients did have transient severe vision loss that resolved. Surveys from at least four other investigators are pending.

Conclusions: : Acute severe visual acuity decrease is an uncommon complication following combination therapy for wet macular degeneration. Further research is necessary to determine the safest and most optimal parameters for this treatment approach.

Keywords: age-related macular degeneration • photodynamic therapy • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×